CA3243960A1 - RHO KINASE INHIBITION COMPOSITIONS AND METHODS - Google Patents
RHO KINASE INHIBITION COMPOSITIONS AND METHODSInfo
- Publication number
- CA3243960A1 CA3243960A1 CA3243960A CA3243960A CA3243960A1 CA 3243960 A1 CA3243960 A1 CA 3243960A1 CA 3243960 A CA3243960 A CA 3243960A CA 3243960 A CA3243960 A CA 3243960A CA 3243960 A1 CA3243960 A1 CA 3243960A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- larazotide
- subject
- derivative
- rock
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308330P | 2022-02-09 | 2022-02-09 | |
| US63/308,330 | 2022-02-09 | ||
| PCT/US2023/062247 WO2023154770A1 (en) | 2022-02-09 | 2023-02-09 | Compositions and methods for inhibiting rho kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243960A1 true CA3243960A1 (en) | 2023-08-17 |
Family
ID=87565095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243960A Pending CA3243960A1 (en) | 2022-02-09 | 2023-02-09 | RHO KINASE INHIBITION COMPOSITIONS AND METHODS |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250144166A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475867A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506487A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119730867A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243960A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023154770A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118873629B (zh) * | 2024-09-27 | 2024-12-10 | 北京大学口腔医学院 | 醋酸拉唑肽在制备促进成骨药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047532A2 (en) * | 2007-10-12 | 2009-04-16 | Cancer Research Technology Limited | Cancer susceptibility loci |
| WO2009132050A2 (en) * | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| JP2020507626A (ja) * | 2017-02-10 | 2020-03-12 | イノベイト バイオファーマシューティカルズ インコーポレイテッド | 腸上皮の透過性と関連する疾患を治療する組成物及び方法 |
| WO2019183036A1 (en) * | 2018-03-19 | 2019-09-26 | Innovate Biopharmaceuticals, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
| KR20220049005A (ko) * | 2019-08-16 | 2022-04-20 | 9 미터스 바이오파마, 인코포레이티드 | 라라조타이드 제형 |
| AU2021255955A1 (en) * | 2020-04-15 | 2022-11-10 | Interlude Biopharma Co. | Larazotide derivatives comprising d-amino acids |
-
2023
- 2023-02-09 CA CA3243960A patent/CA3243960A1/en active Pending
- 2023-02-09 US US18/836,845 patent/US20250144166A1/en active Pending
- 2023-02-09 EP EP23753638.8A patent/EP4475867A4/en active Pending
- 2023-02-09 WO PCT/US2023/062247 patent/WO2023154770A1/en not_active Ceased
- 2023-02-09 JP JP2024547502A patent/JP2025506487A/ja active Pending
- 2023-02-09 CN CN202380032652.0A patent/CN119730867A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023154770A1 (en) | 2023-08-17 |
| EP4475867A1 (en) | 2024-12-18 |
| JP2025506487A (ja) | 2025-03-11 |
| EP4475867A4 (en) | 2026-02-18 |
| US20250144166A1 (en) | 2025-05-08 |
| CN119730867A (zh) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2459018T3 (es) | Formulaciones de efectores de la unión estrecha | |
| US12059397B2 (en) | Calcium lactate compositions and methods of use | |
| RU2016127232A (ru) | Антисмысловые композиции и способы их получения и применения | |
| TR201905226T4 (tr) | Bir gecikmeli salım ilaç formülasyonu. | |
| KR20170029576A (ko) | 골형성단백질의 치료적 용도 | |
| CN121943909A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| US20260034191A1 (en) | Larazotide formulations | |
| US20250144166A1 (en) | Compositions and methods for inhibiting rho kinase | |
| WO2023114984A1 (en) | Tead inhibitors and uses thereof | |
| MG Saez | Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer | |
| Zhang et al. | The ACE2 activator diminazene aceturate ameliorates colitis by repairing the gut-vascular barrier in mice | |
| JP7502832B2 (ja) | 膵癌細胞の浸潤転移抑制剤 | |
| JP2013537221A (ja) | 改良された経口標的化薬物送達システム | |
| CN115956078A (zh) | Akt3调节剂及其使用方法 | |
| CN116390757A (zh) | 用于治疗肿瘤的药物组合物 | |
| KR20230005209A (ko) | D-아미노산을 포함하는 라라조타이드 유도체 | |
| EP4489756A1 (en) | Methods of treating small cell lung cancer | |
| CN121548414A (zh) | Hippo-yap通路调节剂的药物制剂和给药日程 | |
| TWI822897B (zh) | 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途 | |
| CN118217382A (zh) | 使用麦胶蛋白肽治疗癌症的套件和方法 | |
| Dayanc et al. | Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue | |
| WO2017095826A1 (en) | Combination therapy for treatment of melanoma | |
| Dayanc et al. | Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is | |
| Zhao et al. | Zolbetuximab combined with chemotherapy in a patient with CLDN18. 2-positive advanced gastric cancer undergoing hemodialysis: a case report | |
| Hao et al. | Breaking the'Undruggable'Barrier: Nanoparticle-Based Combination Therapy Utilizing Sotorasib and PD-L1 Inhibitor for Treating Non-Small Cell Lung Cancer Patients with KRASG12C Mutations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240809 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240812 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240812 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250205 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250207 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250219 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260127 |